Undisclosed programs RD oncology, autoimmune diseases, allergies
Neoleukin Therapeutics is developing novel interleukin-2 (IL-2) therapies to fight cancer. The company's unique science is based on its proprietary IL-2 activation platform, which is designed to overcome the key challenges of IL-2 therapy, including (1) Side effects: IL-2 can cause severe side effects, including fever, fatigue, and organ toxicity. Neoleukin's IL-2 activation platform is designed to minimize these side effects by selectively activating IL-2 in the tumor microenvironment. (2) Limited efficacy: IL-2 has shown limited efficacy in the treatment of solid tumors. Neoleukin's IL-2 activation platform is designed to enhance the efficacy of IL-2 by activating it in the presence of tumor cells.